Micardis® in Patients With Essential Hypertension

Completed

• Conditions: Hypertension
• Interventions: Drug: Telmisartan tablets

• Registration Number: NCT02187705
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals

Detailed Description

Not available

Study Timeline

• Study Start: 1999-05
• Primary Completion: 2000-05
• Status Verified: 2014-07
• Study First Submitted: 2014-07-09
• Study First Submitted QC: 2014-07-10
• Last Update Submitted: 2014-07-10
• Study First Posted: 2014-07-11
• Last Update Posted: 2014-07-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1688

Inclusion Criteria

• Patients with essential hypertension
• Minimum age of 18 years

Exclusion Criteria

Not applicable

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with normotension at baseline	Telmisartan tablets	-
Patients with essential hypertension at baseline	Telmisartan tablets	-
Patients with isolated hypertension at baseline	Telmisartan tablets	-

Primary Outcome Measures

Name	Time	Method
Number of patients with adverse events	Up to 14 days
Changes from baseline in blood pressure	Up to 14 days	Evaluation was performed separately for three patient groups depending on their hypertension status at baseline (normotension, essential hypertension and isolated hypertension)